SB
ELEV

Samsara BioCapital’s Elevation Oncology ELEV Stock Holding History

Samsara BioCapital’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-830,565
Closed -$1.26M – 43
2023
Q2 		$1.26M Hold
830,565
– – 0.22% 35
2023
Q1 		$1.58M Hold
830,565
– – 0.33% 35
2022
Q4 		$789K Hold
830,565
– – 0.17% 40
2022
Q3 		$939K Hold
830,565
– – 0.22% 43
2022
Q2 		$1.16M Sell
830,565
-101,675
-11% -$255K 0.31% 43
2022
Q1 		$2.35M Hold
932,240
– – 0.59% 35
2021
Q4 		$5.61M Hold
932,240
– – 1.09% 22
2021
Q3 		$7.26M Buy
932,240
+1
+0% +$11 1.14% 21
2021
Q2 		$12.7M Buy
+932,239
New +$11.5M 1.56% 16

Other funds holding ELEV

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Samsara BioCapital's ELEV Position: Q3 2023 in Review

Samsara BioCapital sold out of Elevation Oncology (ELEV) in Q3 2023, closing a stake of 830,565 shares — an estimated $1.26M sold.

Samsara BioCapital first reported a position in ELEV in Q2 2021 and held it in 9 quarters. The position peaked at $12.7M in Q2 2021. 41 funds tracked by Wall St. Rank hold ELEV as of Q3 2023.

  • Samsara BioCapital reported no remaining Elevation Oncology position as of Q3 2023 after selling out during the quarter.
  • Samsara BioCapital sold 830,565 Elevation Oncology shares in Q3 2023, an estimated $1.26M.
  • Samsara BioCapital first reported a position in Elevation Oncology in Q2 2021 and held it in 9 quarters.
  • Samsara BioCapital's Elevation Oncology position peaked at $12.7M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2023.

Based on Samsara BioCapital's 13F filing for Q3 2023, filed 14 Nov 2023.